NOVATO, Calif., April 2, 2026
Ultragenyx Pharmaceutical Inc. has reached a significant regulatory milestone as the U.S. Food and Drug Administration (FDA) accepted its Biologics License Application (BLA) resubmission for UX111 (rebisufligene etisparvovec), an investigational AAV9 gene therapy for the treatment of Sanfilippo syndrome Type A (MPS IIIA). The agency has set a PDUFA action date of September 19, 2026, bringing the therapy closer to potential approval as the first-ever treatment for this rare and fatal pediatric neurodegenerative disorder. This development underscores growing momentum in gene therapy innovation targeting ultra-rare genetic diseases with high unmet medical need.
Regulatory Milestone Signals Potential First-in-Class Therapy
The FDA acceptance of the UX111 BLA resubmission marks a crucial step toward delivering a disease-modifying therapy for patients suffering from Sanfilippo syndrome Type A, a condition with no currently approved treatments. The application is supported by long-term clinical data, including up to eight years of follow-up, demonstrating sustained clinical benefit, improved neurodevelopmental outcomes, and durable biomarker responses. The FDA had previously acknowledged the robust neurodevelopmental data and supportive biomarker evidence, strengthening the case for accelerated approval.
UX111 has also received multiple regulatory designations, including Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Rare Pediatric Disease, and Orphan Drug status, highlighting its potential to address a critical unmet need in rare pediatric disorders.
Gene Therapy Targets Root Cause of Neurodegeneration
Advertisement
UX111 is a one-time intravenous AAV9 gene therapy designed to deliver a functional copy of the SGSH gene, addressing the underlying enzyme deficiency responsible for heparan sulfate accumulation in the brain. By restoring sulfamidase enzyme activity, the therapy aims to prevent progressive cellular damage and neurodegeneration, which are hallmarks of MPS IIIA.
The mechanism enables treated cells to produce and distribute the functional enzyme throughout the brain, offering a systemic and sustained therapeutic effect. Clinical findings indicate that UX111 can slow or potentially halt disease progression, representing a transformative approach compared to supportive care alone. The therapy’s ability to target the root genetic cause of disease positions it at the forefront of next-generation precision medicine and gene therapy advancements.
Addressing a Devastating Rare Pediatric Disease
Sanfilippo syndrome Type A is a rare lysosomal storage disorder characterized by rapid neurodegeneration, cognitive decline, behavioral abnormalities, and early mortality, with a median life expectancy of approximately 15 years. Affecting an estimated 3,000 to 5,000 patients globally, the disease imposes a profound burden on patients and families due to its progressive and irreversible nature.
The absence of approved therapies has made treatment largely supportive, emphasizing the urgent need for innovative therapeutic solutions. If approved, UX111 would not only become the first disease-modifying therapy for MPS IIIA but also establish a new benchmark in the treatment of genetic neurodegenerative disorders. Additionally, Ultragenyx has confirmed that manufacturing capabilities are fully established within the United States, ensuring readiness for potential commercialization and patient access.
With the FDA’s acceptance of the BLA resubmission and a defined regulatory timeline, UX111 stands as a promising breakthrough in gene therapy, offering hope for children affected by one of the most devastating rare diseases while reinforcing the expanding role of advanced biologics in transforming modern medicine.
Source: Ultragenyx Pharmaceutical Inc press release
